




PCT/GB 2003 / 0 0 3 2 0 1  
CT/PTO 26 JAN 2005

INVESTOR IN PEOPLE

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*R. Mahoney*

Dated 14 August 2003

BEST AVAILABLE COPY

## Patents Form 1/77

Patents Act 1977  
(Rule 16)The  
Patent  
Office26JUL02 036168/1 002835  
P01/770050.00-0217298.9THE PATENT OFFICE  
A

26 JUL 2002

RECEIVED BY FAX

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP9 1RH

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference **GS/JS/P207266**
2. Patent application number **0217298.9**  
(The Patent Office will fill in this part) **26 JUL 2002**
3. Full name, address and postcode of the or of each applicant (underline all surnames)  
**UNIVERSITY OF SHEFFIELD  
FIRTH COURT  
WESTERN BANK  
SHEFFIELD, S10 2TN, UNITED KINGDOM**  
Patents ADP number (if you know it) **007.98454004**  
If the applicant is a corporate body, give the country/state of its incorporation **UNITED KINGDOM**
4. Title of the invention **POLYMER**
5. Name of your agent (if you have one) **URQUHART-DYKES & LORD**  
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)  
**TOWER HOUSE  
MERRION WAY  
LEEDS  
LS2 8PA**  
**HARRISON GODDARD FOOTE  
FOUNTAIN PRECINCT  
LEOPOLD ST  
SHEFFIELD S1 2RD**  
**7914237001**  
Patents ADP number (if you know it) **1644004**
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number
- | Country | Priority application number (if you know it) | Date of filing (day / month / year) |
|---------|--|-------------------------------------|
|         |  |                                     |
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application
- | Number of earlier application | Date of filing (day / month / year) |
|-------------------------------|-------------------------------------|
|                               |                                     |
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if)
- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 17

Claim(s)

Abstract

Drawing(s) 2

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 1/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

26/7/02

12. Name and daytime telephone number of person to contact in the United Kingdom

GARRY P STUTTARD - 0113 2452388

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

DUPLICATE

## POLYMER

The present invention relates to hyperbranched polyamidoamines which are useful in *inter alia* gene transfection, to its compositions with useful agents, to its uses and to a process for preparing hyperbranched polyamidoamines in a single step.

Gene therapy is a new and potentially revolutionary technology which could dramatically restructure the way in which certain diseases are treated and possibly provide cures for currently untreatable genetic diseases. Advances in this technology are being seriously hampered by the lack of effective, safe and cheap transfection agents capable of delivering therapeutic genes to the patient. Moreover, laboratory research is suffering due to the lack of efficient and versatile transfection agents required for preliminary investigations into new therapies.

As used herein, a vector is a compound which can deliver DNA into cell lines. The present market for gene transfection is dominated by viral (*ie* retroviral or adenoviral) or non-viral vectors such as synthetic cationic liposomes (lipoplexes). Viral vectors are very efficient at delivering DNA into cells but have several drawbacks including the need for specialist handling conditions, immunogenicity and potentially serious side effects (such as recombination of viral DNA with host DNA). The leading non-viral vector is LIPOFECTAMINE<sup>®</sup>. The main disadvantage of this lipid based vector is that it is toxic and has limited use *in vivo* being a dynamic structure which can easily fall apart below a certain critical concentration. Several attempts have been made to modify the structure of the lipid to make it less toxic (for example by adding biocompatible molecules). To date, none of these attempts have been successful and toxicity is still the major drawback.

Other non-viral vectors available on the market include polyamidoamine (PAMAM) dendrimers and several other synthetic polymers (polyplexes) which are mostly linear in structure or possess very limited branching (such as polyethyleneimine, polylysine and several other amino acid derived polymers). PAMAM dendrimers may be used intact or partially degraded (often being referred to as activated dendrimers (*eg* SUPERFECT<sup>®</sup>)). Generally these agents require activation (*eg* by thermal degradation).

Dendrimers and hyperbranched polymers are attracting increasing levels of interest in various fields of research. The molecules of a dendrimer are characterised by highly regular and radially symmetrical branching about a nitrogen core. The degree of branching is 100% and dendrimers exhibit a precisely defined molecular weight. The synthesis of dendrimers using iterative synthetic procedures is well established. For

example, US-A-4568737, US-A-4587329, US-A-4558120, US-A-4507466 and US-A-4435548 describe the preparation of symmetrical (*ie*  $\text{NR}_3$ ) PAMAM dendrimers by performing on a core moiety (such as ammonia) successive Michael additions and amidation using excess reagents or successive amidation and alkylation steps.

Lim *et al*, J Am Chem Soc, 2001, 123, 2460-2461 discloses the use of a certain hyperbranched polyaminoester for genes transfection. The hyperbranched polyaminoester was prepared by a PAMAM synthesis and modified prior to use as a transfecting agent. Lim *et al* reported that the modified polyaminoester could transfect DNA and exhibited low toxicity. However, several synthetic steps are required to synthesise the polyaminoester and the transfection efficiency is low.

The present invention is based on the recognition that certain hyperbranched polyamidoamines are useful in *inter alia* gene transfection. More particularly, the present invention seeks to provide improvements in gene transfection available from certain hyperbranched polyamidoamines which may be both efficient and safe for use in clinical applications.

Thus viewed from a first aspect the present invention provides a hyperbranched polyamidoamine whose molecules are characterised by a nitrogen core linked to:

- a first irregularly branched amidoamine unit terminating in an amine group or a functional derivative thereof;
- a second irregularly branched amidoamine unit terminating in an amine group or a functional derivative thereof; and
- a third irregularly branched amidoamine unit terminating in a carboxylic acid or related group or a functional derivative thereof.

The molecules of the hyperbranched polyamidoamine of the invention are collectively characterised by the irregularity of the branching in the first, second and third amidoamine units and it is this which distinguishes them structurally over dendrimers and may account for their more favourable properties. Due to the irregularity of the branching, a hyperbranched polyamidoamine of the invention is not generally characterisable by MS or NMR and (unlike a dendrimer) exhibits a broad GPC trace.

The hyperbranched polyamidoamines of the invention have potentially extensive utility in numerous systems. Broadly speaking, they offer a multiplicity of functional groups together with a large surface area and internal volume and as such may be widely exploited as carriers, supports or substrates. The hyperbranched polyamidoamines of the invention are typically stable for lengthy periods (*eg* one year or more) and may be at least as effective in gene transfection as the market leaders. They are structurally more

flexible than dendrimers and may have the advantage of being water soluble.

Preferably the hyperbranched polyamidoamine can have a theoretical degree of branching up to 50%, particularly preferably up to 67%, more preferably up to 75%, most preferably up to 80%.


Preferably each of the first, second and third irregularly branched amidoamine units which may be the same or different includes consecutive, irregularly branched amidoamine moieties each having two or more (preferably two or three) amido groups.

Preferably the amine group or functional derivative thereof (in which the first and second irregularly branched amidoamine unit terminates) is a primary amine group or a functional derivative thereof. The functional derivative of the amine group may be chosen to suit the desired function of the hyperbranched polyamidoamine. For example, the functional derivative may be a secondary, tertiary or quaternary amine group, an aromatic or aliphatic amide group, a cyano group, a sulphur containing group (eg a thioamide group), a cross-linking group (eg for cross-linking to other polymers or oligomers), an anilino group or an acyclic polynitrogen group (eg a guanidino, biguanidino, triguanidino or ureido group).

Preferably the functional derivative is an amine group substituted with one, two or three C<sub>1-6</sub>-alkyl groups (eg methyl groups) or with an *N,N*-substituted amidoamine group. Preferably the functional derivative is a quaternary amine group which is cationic and can be advantageously exploited for binding DNA in gene transfection.

Preferably the related group of the carboxylic acid is selected from the group consisting of a salt, ester, anhydride, acid halide (eg chloride), acyl, amide, imide, nitrile, aldehyde and hydrazide. The functional derivative may be a carboxyl protecting or blocking group or a group chosen to suit the desired function of the hyperbranched polyamidoamine. Preferably the third irregularly branched amidoamine unit terminates in a carboxylic acid group or a functional derivative thereof.

Preferably the molecules of the hyperbranched polyamidoamine are characterised by formula I:



wherein:


Y is a divalent bridging group;

T together with the group CO to which it is bound is the carboxylic acid or related group

or the functional derivative thereof;

T<sup>1</sup> together with the nitrogen to which it is bound is the amine group or functional derivative thereof;

R<sup>1</sup> is an amidoamine unit of formula II:



(wherein:

each of X and Y' which may be the same or different is a divalent bridging group;

R<sup>4</sup> is either

(a) n consecutive amidoamine moieties of formula III:




(wherein:

s is 0 or 1;

n is a number greater than 0;

each of X' and Y'' which may be the same or different is a divalent bridging group) or


(b) an amidoamine unit of formula IV



(wherein:

R<sup>6</sup> is either

(a) m consecutive amidoamine moieties of formula V:




(wherein:

m is a number greater than 0;

each of X'' and Y''' which may be the same or different is a divalent bridging group) or

(b) an amidoamine unit of formula VI


(VI)



(wherein:

$R^8$  is x consecutive amidoamine moieties of formula VII:

(VII)



(wherein:

x is a number greater than 0;

each of  $X'''$  and  $Y'''$  which may be the same or different is a divalent bridging group; and

$R^9$  is  $T^1$  or is a group as hereinbefore defined for  $R^8T^1$ ; and

$R^7$  is  $T^1$  or is a group as hereinbefore defined for  $R^6T^1$ ; and

$R^5$  is  $T^1$  or a group as hereinbefore defined for  $R^4T^1$ ; and

$R^2$  is as hereinbefore defined for  $R^1T^1$ ; and

$R^3$  is either


(a) p consecutive amidoamine moieties of formula VIII:



(wherein:

p is a number of more than zero)


or (b) q consecutive amidoamine moieties of formula IX:



(wherein:

q is a number greater than 0)

or (c) y consecutive amidoamine moieties of formula X



(wherein:



y is a number greater than 0).

For the avoidance of doubt,  $R^1$  may be the same as or different from  $R^2$  (but preferably is the same),  $R^4$  may be the same as or different from  $R^5$  (but preferably is the same),  $R^6$  may be the same as or different from  $R^7$  (but preferably is the same) and  $R^8$  may be the same as or different from  $R^9$  (but preferably is the same)

In a first preferred embodiment,  $R^4$  is option (a) and s is 0.

In a second preferred embodiment,  $R^4$  is option (a) and s is 1.

In a third preferred embodiment,  $R^4$  is option (b) and  $R^6$  is option (a).

In a fourth preferred embodiment,  $R^4$  is option (b) and  $R^6$  is option (b).

The average molecular weight molecule is represented by the aforementioned formula I in which  $n+p$  or  $m+q$  or  $x+y$  is in the range 1 to 20.

Each of Y, Y', Y'', Y''', Y''', X, X', X'' and X''' which may be the same or different may be a cyclic (eg monocyclic) hydrocarbon (eg aromatic hydrocarbon) bridging group, an acyclic heteroatomic bridging group, a heterocyclic (eg heteroaromatic) bridging group or an acyclic hydrocarbon bridging group (which itself is optionally interrupted by or terminates in one or more of a cyclic (eg monocyclic) hydrocarbon (eg aromatic hydrocarbon) group, an acyclic heteroatomic group, a heterocyclic (eg heteroaromatic) group or amide group). The bridging groups should be chosen so as not to interfere with polymerisation.

By way of example, each of Y, Y', Y'', Y''', Y''', X, X', X'' and X''' which may be the same or different may be a  $C_{1-12}$ -alkylene or  $C_{1-12}$ -alkenylene bridging group (preferably a  $C_{1-6}$ -alkylene, particularly preferably a  $C_{1-4}$ -alkylene bridging group) optionally interrupted by or terminating in an oxygen atom, one, two or three optionally (but preferably) substituted nitrogen atoms, a cyclic (eg monocyclic) hydrocarbon (eg aromatic hydrocarbon) group, a heterocyclic (eg heteroaromatic) group or an amide group.

Preferably each of Y, Y', Y'', Y''', Y''', X, X', X'' and X''' which may be the same or different is a  $C_{1-6}$ -alkylene, particularly preferably is a  $C_{1-4}$ -alkylene bridging group (eg ethylene). Preferably each of Y, Y', Y'', Y''', Y''', X, X', X'' and X''' is ethylene.

Preferably T is selected from the group consisting of Cl, O-CO- $R^{10}$ ,  $NHR^{12}$ ,  $-NH$ ,  $=N$ , H, OR<sup>11</sup> and OMet (wherein each of  $R^{10}$  and  $R^{11}$  which may be the same or different is hydrogen or an optionally substituted  $C_{1-12}$ -alkyl group (eg  $C_{1-6}$ -alkyl group);  $R^{12}$  is hydrogen, an optionally substituted  $C_{1-12}$ -alkyl group (eg  $C_{1-6}$ -alkyl group) or  $NHR^{10}$ ; and Met is a metal (eg an alkali or alkaline earth metal)). Preferably T is hydroxyl.

Preferably  $T^1$  is selected from the group consisting of hydrogen and N-substituents

rendering the nitrogen to which they are bound a functional derivative of amine (eg one or two C<sub>1-6</sub>-alkyl (eg methyl) groups).

In a preferred embodiment, the hyperbranched polyamidoamine is obtainable by polymeric condensation of a compound in which a nitrogen core is linked to:

- a first amidoamine, (N,N-diamidoamine)amidoamine, N,N-di(N,N-diamidoamine)amidoamine or N,N-di(N,N-di(N,N-diamidoamine)amidoamine)amidoamine unit terminating in an amine group;
- a second amidoamine, (N,N-diamidoamine)amidoamine, N,N-di(N,N-diamidoamine)amidoamine or N,N-di(N,N-di(N,N-diamidoamine)amidoamine)amidoamine unit terminating in an amine group; and
- a third unit terminating in a carboxylic acid or related group.

From a further patentable viewpoint, the present invention seeks to provide an improved process for preparing hyperbranched polyamidoamines which is advantageously carried out in a single step. More particularly, the process relates to a single step synthesis of a hyperbranched polyamidoamine with a broad molecular weight distribution by polycondensation without the need for additional functionalisation steps such as thermal degradation.

Viewed from a further aspect the present invention provides a process for preparing a hyperbranched polyamidoamine comprising:

(A) inducing polymeric condensation of a compound in which a nitrogen core is linked to:

- a first amidoamine, (N-amidoamine)amidoamine, N-(N-amidoamine)amidoamine or N-(N-(N-amidoamine)amidoamine)amidoamine unit terminating in an amine group;
- a second amidoamine, (N-amidoamine)amidoamine, N-(N-amidoamine)amidoamine or N-(N-(N-amidoamine)amidoamine)amidoamine unit terminating in an amine group; and
- a third unit terminating in a carboxylic acid or related group.

In a preferred embodiment of the process, the nitrogen is linked to

- a first amidoamine, (N,N-diamidoamine)amidoamine, N,N-di(N,N-diamidoamine)amidoamine or N,N-di(N,N-di(N,N-diamidoamine)amidoamine)amidoamine unit terminating in an amine group;
- a second amidoamine, (N,N-diamidoamine)amidoamine, N,N-di(N,N-diamidoamine)amidoamine or N,N-di(N,N-di(N,N-diamidoamine)amidoamine)amidoamine unit terminating in an amine group; and


a third unit terminating in a carboxylic acid or related group.

The process advantageously leads to short manufacturing times and requires non-specialist equipment (eg standard laboratory equipment) so is uncostly.

Preferably the amine group is a primary amine group.

Preferably the related group of the carboxylic acid is selected from the group consisting of a salt, ester, anhydride, acid halide (eg chloride), acyl, amide, imide, nitrile, aldehyde and hydrazide. Preferably the third unit terminates in a carboxylic acid group.

In a preferred embodiment, the compound is of formula XI



wherein:

Y is as hereinbefore defined;

R<sup>15</sup> is as hereinbefore defined for group T;

each of R<sup>13</sup> and R<sup>14</sup> which may be the same or different is a group -Y'-CO-NH-X-NH<sub>2</sub>, -Y'-CO-NH-X-NR<sup>16</sup>(Y''-CO-NH-X'-NR<sup>17</sup>R<sup>18</sup>) (wherein R<sup>16</sup> is hydrogen or -Y'''-CO-NH-X'-NR<sup>17</sup>R<sup>18</sup>; each of R<sup>17</sup> and R<sup>18</sup> which may be the same or different is hydrogen or -Y'''-CO-NH-X''-NR<sup>19</sup>R<sup>20</sup> (wherein each of R<sup>19</sup> and R<sup>20</sup> which may be the same or different is hydrogen or -Y''''-CO-NH-X'''-NH<sub>2</sub>); and Y', X, X', X'', X''', Y'', Y''' and Y'''' are as hereinbefore defined).

Preferably R<sup>15</sup> is hydroxyl.

In a first preferred embodiment, R<sup>13</sup> and R<sup>14</sup> are both the group -Y'-CO-NH-X-NH<sub>2</sub> (an AB<sup>2</sup>-type monomer).

In a second preferred embodiment, R<sup>13</sup> and R<sup>14</sup> are both the group -Y'-CO-NH-X-N-(Y''-CO-NH-X'-NH<sub>2</sub>)<sub>2</sub> (an AB<sup>4</sup>-type monomer).


In a third preferred embodiment, R<sup>13</sup> and R<sup>14</sup> are both the group -Y'-CO-NH-X-N-(Y''-CO-NH-X'-N(Y'''-CO-NH-X''-NH<sub>2</sub>)<sub>2</sub>)<sub>2</sub> (an AB<sup>8</sup>-type monomer).

In a fourth preferred embodiment, R<sup>13</sup> and R<sup>14</sup> are both the group -Y'-CO-NH-X-N-(Y''-CO-NH-X'-N(Y'''-CO-NH-X''-N(Y''''-CO-NH-X'''-NH<sub>2</sub>)<sub>2</sub>)<sub>2</sub>)<sub>2</sub> (an AB<sup>16</sup>-type monomer).

Particularly preferably the compound of formula XI is an AB<sup>2</sup>-type or AB<sup>4</sup>-type monomer.

In the first preferred embodiment, step (A) is preferably preceded by:

(A0) reacting a diamine of formula NH<sub>2</sub>-X-NH<sub>2</sub> with a compound of formula XII:



(wherein  $\text{R}^{21}$  and  $\text{R}^{22}$  which may be the same or different are as hereinbefore defined for group T and  $\text{Y}'$ ,  $\text{R}^{15}$  and Y are as hereinbefore defined). Preferably each of  $\text{R}^{21}$  and  $\text{R}^{22}$  which may be the same or different (but preferably are the same) is an  $\text{OC}_{1-6}$ -alkyl group, particularly preferably OMe.

In the first preferred embodiment, step (A0) is preferably preceded by:


(A00) reacting a compound of formula XIII:



(wherein Y and  $\text{R}^{15}$  are as hereinbefore defined) with a Michael addition reagent.

In the second preferred embodiment, step (A) is preferably preceded by:


(A'0) reacting a diamine of formula  $\text{NH}_2\text{-X'-NH}_2$  with a compound of formula XIV:



(wherein  $\text{R}^{23}$  and  $\text{R}^{24}$  which may be the same or different are as hereinbefore defined for group T and X,  $\text{X}'$ , Y,  $\text{Y}'$  and  $\text{Y}''$  are as hereinbefore defined). Preferably each of  $\text{R}^{23}$  and  $\text{R}^{24}$  which may be the same or different (but preferably are the same) is an  $\text{OC}_{1-6}$ -alkyl group, particularly preferably OMe.

In the second preferred embodiment, step (A'0) is preferably preceded by:

(A'00) reacting a compound of formula XV:




(wherein Y and  $\text{R}^{15}$  are as hereinbefore defined; and each of  $\text{R}^{25}$  and  $\text{R}^{26}$  which may be the same or different is a group  $\text{-Y'-CO-NH-X-NH}_2$  wherein X and  $\text{Y}'$  are as hereinbefore defined) with a Michael addition reagent.

The compound of formula XV may itself be prepared from a compound of formula XII by step (A0) as hereinbefore defined.

In the third preferred embodiment, step (A) is preferably preceded by:


(A''0) reacting a diamine of formula  $\text{NH}_2\text{-X''-NH}_2$  with a compound of formula XVI:



(wherein  $\text{R}^{27}$  and  $\text{R}^{28}$  which may be the same or different are as hereinbefore defined for group T and X,  $\text{X'}$ ,  $\text{X''}$ , Y,  $\text{Y'}$ ,  $\text{Y''}$  and  $\text{Y'''}$  are as hereinbefore defined). Preferably each of  $\text{R}^{27}$  and  $\text{R}^{28}$  which may be the same or different (but preferably are the same) is an  $\text{OC}_{1-6}$ -alkyl group, particularly preferably OMe.

In the third preferred embodiment, step (A''0) is preferably preceded by:

(A''00) reacting a compound of formula XVII:




(wherein Y and  $\text{R}^{15}$  are as hereinbefore defined; and each of  $\text{R}^{29}$  and  $\text{R}^{30}$  which may be the same or different is a group  $\text{Y'-CO-NH-X-N-Y''-CO-NH-X'-NH}_2$  wherein X,  $\text{X'}$ ,  $\text{Y'}$  and  $\text{Y''}$  are as hereinbefore defined) with a Michael addition reagent.

The compound of formula XVII may itself be prepared from a compound of formula XIV by step (A'0) as hereinbefore defined.

In the fourth preferred embodiment, step (A) is preferably preceded by:

(A'''0) reacting a diamine of formula  $\text{NH}_2\text{-X'''-NH}_2$  with a compound of formula XVIII:




(wherein  $\text{R}^{31}$  and  $\text{R}^{32}$  which may be the same or different are as hereinbefore defined for group T and X,  $\text{X'}$ ,  $\text{X''}$ ,  $\text{X'''}$ , Y,  $\text{Y'}$ ,  $\text{Y''}$ ,  $\text{Y'''}$  and  $\text{Y''''}$  are as hereinbefore defined).

Preferably each of  $R^{31}$  and  $R^{32}$  which may be the same or different (but preferably are the same) is an  $OC_{1-6}$ -alkyl group, particularly preferably OMe.

In the fourth preferred embodiment, step (A'''0) is preferably preceded by:

(A'''00) reacting a compound of formula XIX:



(wherein Y and  $R^{15}$  are as hereinbefore defined; and each of  $R^{33}$  and  $R^{34}$  which may be the same or different is a group  $Y'-CO-NH-X-N-Y''-CO-NH-X'-N-Y'''-CO-NH-X''-NH_2$  wherein X, X', X'', Y', Y'' and Y''' are as hereinbefore defined) with a Michael addition reagent.

The compound of formula XIX may itself be prepared from a compound of formula XVI by step (A''0) as hereinbefore defined.

Steps (A0), (A'0), (A''0) and (A'''0) may be carried out in a suitable solvent (eg an alcohol such as methanol) at low temperature (eg 0°C).

The Michael addition of steps (A00), (A'00), (A''00) and (A'''00) may exploit any conventional Michael addition reagent. Preferred is an alkyl acrylate (such as a  $C_{1-6}$ -alkyl acrylate), particularly preferably methyl acrylate. Typically the alkyl acrylate is present in acetonitrile or the corresponding alkyl alcohol (eg methanol for methyl acrylate).

Polymeric condensation may be induced conventionally, eg thermally or using an amide coupling agent. The latter has the advantage that polymeric condensation may be carried out at room temperature.

Thermal condensation is typically carried out at an elevated temperature in excess of 100°C (eg 200°C) and may be carried out at less than ambient pressure (eg under high vacuum such as at about 0.5mmHg).

Polymeric condensation may be carried out using an amide coupling agent. Numerous amide coupling agents are known to the skilled person (see *inter alia* Handbook of Reagents for Organic Synthesis: Activating Agents and Protecting Groups, A. J. Pearson and W. R. Roush. John Wiley and Sons, Chichester, 1999) and include triphenylphosphite/pyridine in N-methylpyrrolidinone (NMP) typically at a temperature in the range 40-200°C, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) in NMP typically at a temperature in the range 20-100°C or

4-(4,6-dimethoxy-1,3,5-triazin-2yl)-4-methylmorpholinium chloride (DMT-MM) in methanol or water typically at room temperature.

The product may be purified via preparative column chromatography (for high grade products) or dialysis (for general use).

The process may further comprise the step of:

(B1) functionally derivatising the amine groups in which the first and second irregularly branched amidoamine units terminate.

The process may further comprise the step of:

(B2) functionally derivatising the carboxylic acid or related group in which the third irregularly branched amidoamine unit terminates.

Suitable reagents and conditions for steps (B1) and (B2) will be familiar to those skilled in the art. For example, step (B1) comprises rendering the terminal amine groups cationic (eg in aqueous solution).

Viewed from a yet further aspect the present invention provides a composition comprising a hyperbranched polyamidoamine as hereinbefore defined together with an agent selected from the group consisting of a therapeutically or prophylactically active agent, an *in vivo* occurring or *in vitro* generated nucleotide (eg a polynucleotide or oligonucleotide such as a virus or fragment thereof, expression vector, gene or fragment thereof, DNA (eg a single, double or multiple strand thereof) or RNA (eg a single, double or multiple strand thereof)), a diagnostic agent (eg a diagnostic contrast agent being or containing a radionuclidic, paramagnetic, superparamagnetic, ferromagnetic, ferrimagnetic, antiferromagnetic, diamagnetic, fluorescent, phosphorescent, luminescent, chemiluminescent, X-ray absorbent, UV absorbent, IR absorbent or ultrasound absorbent species), a pesticide, a toxin, a protein (eg an immunoglobulin such as an antibody (or fragment thereof)), an antigen, a peptide, a nucleic acid, an amino acid and a bioactive agent.

The hyperbranched polyamidoamine may couple with, encapsulate, complex or bond to (eg covalently bond to) the agent. For use *in vivo*, the composition is in pharmaceutically acceptable form and where appropriate may further comprise one or more physiologically tolerable carriers, adjuvants or excipients. Typically the composition is a solution, suspension or emulsion (eg an aqueous solution, suspension or emulsion).

In a preferred embodiment, the composition comprises:

a hyperbranched polyamidoamine as hereinbefore defined bound to a nucleotide or polynucleotide (such as a virus or fragment thereof, expression vector, gene or fragment

thereof, DNA (eg a single, double or multiple strand thereof) or RNA (eg a single, double or multiple strand thereof)). By way of example, the DNA or RNA may be genomic DNA, mRNA, cDNA or aRNA. Particularly preferably the composition comprises: a hyperbranched polyamidoamine as hereinbefore defined bound to DNA (eg a single, double or multiple strand thereof).

The hyperbranched polymer may be used to transfect cells or tissues *in vitro* (eg by straightforward incubation techniques in suitable media familiar to those skilled in the art) or *in vivo* by suitable administration protocols (eg routes and doses).

For use as an *in vivo* transfection agent, the composition is preferably an aqueous solution of the hyperbranched polyamidoamine. For example, the transfection agent may be a buffered aqueous solution of the hyperbranched polyamidoamine. For example, approximately 1mg of the hyper branched polyamidoamine of the invention may be provided in a buffered aqueous solution of 1ml.

Viewed from a yet still further aspect the present invention provides hyperbranched polyamidoamines (or compositions thereof) for use in therapy or prophylaxy.

Preferably the hyperbranched polyamidoamine (or composition thereof) for use in therapy or prophylaxy in accordance with this yet still further aspect of the invention is as hereinbefore defined.

In an embodiment, the hyperbranched polyamidoamine is used in therapy or prophylaxy as a delivery agent for a therapeutically or prophylactically active agent (eg drug).

In a preferred embodiment, the hyperbranched polyamidoamine is used in gene therapy or prophylaxy. Preferably the hyperbranched polyamidoamine is used in gene therapy or prophylaxy as a nucleotide (eg DNA) carrier, a transfection agent or a vector.

The hyperbranched polyamidoamines of the invention are exceedingly versatile and may be used in numerous fields.

Viewed from an even still further aspect the present invention provides the use (*in vivo* or *in vitro*) of a hyperbranched polyamidoamine as hereinbefore defined as a carrier, substrate or support.

The use of the hyperbranched polyamidoamine is preferably as a nucleotide (eg DNA) carrier, transfection agent or vector, or as a support or substrate (eg a solution phase support or substrate) in combinatorial chemistry, catalysis, surface coating, implant coating and photoactive systems.

Viewed from a yet even still further aspect the present invention provides the use of a hyperbranched polyamidoamine for the preparation of a composition (eg medicament).



for combatting (eg treating or preventing) genetically related conditions or disorders.

Preferably the hyperbranched polyamidoamine in accordance with this yet even still further aspect of the invention is as hereinbefore defined.

As novel intermediates, certain compounds of formula XI defined hereinbefore form a further patentable aspect of the invention.

Viewed from an even further aspect the present invention provides an intermediate of formula XI as hereinbefore defined.

In a first preferred embodiment of the intermediate,  $R^{13}$  and  $R^{14}$  are both the group  $-Y'-CO-NH-X-NH_2$ .

In a second preferred embodiment of the intermediate,  $R^{13}$  and  $R^{14}$  are both the group  $-Y'-CO-NH-X-N-(Y''-CO-NH-X'-NH_2)_2$ .

In a third preferred embodiment of the intermediate,  $R^{13}$  and  $R^{14}$  are both the group  $-Y'-CO-NH-X-N-(Y''-CO-NH-X'-N(Y'''-CO-NH-X''-NH_2)_2)_2$ .

In a fourth preferred embodiment of the intermediate,  $R^{13}$  and  $R^{14}$  are both the group  $-Y'-CO-NH-X-N-(Y''-CO-NH-X'-N(Y'''-CO-NH-X''-N(Y''''-CO-NH-X'''-NH_2)_2)_2)_2$ .

The present invention will now be illustrated in a non-limitative manner with reference to the following Example and Figures 1 and 2 in which:

Figure 1 illustrates the synthetic steps for preparing  $AB_2$  and  $AB_4$  type monomers; and Figure 2 illustrates preliminary results for transfection using hyperbranched polymers of the invention.

### Example

The synthesis of monomers for polymerisation is initiated from a  $\beta$ -alanine core 1 and follows a two-step (for an  $AB_2$  type monomer) or four-step (for an  $AB_4$  type monomer) iterative procedure (see Figure 1). Growth of the monomer (PAMAM) units is performed by standard PAMAM synthesis described elsewhere (see for example Tomalia *et al*; Polym. J. (Tokyo), 1985, 17, 117-132).

### **Specific Conditions for the Synthesis of Intermediate 2**

A 250ml round-bottomed flask was charged with the reagents  $\beta$ -alanine 1 (20g, 0.225moles), methyl acrylate (80ml, 0.9moles) and triethylamine (65ml, 0.46moles) then the mixture dissolved in anhydrous methanol (250ml). The solution was cooled to 0°C in

ice and stirred under a dry atmosphere for 1 hour. The reaction was then stirred for 2 days at room temperature. After the reaction was complete the excess reagents and solvent were removed under reduced pressure to give a free-flowing honey coloured oil, yield 99%. 250MHz NMR  $\text{CDCl}_3$   $\delta_{\text{H}}$  2.37 (t, 2H,  $\text{CH}_2\text{COOH}$ ); 2.47 (t, 4H,  $\text{CH}_2\text{CO}$ ); 2.74 (t, 2H,  $\text{CH}_2\text{CH}_2\text{COOH}$ ); 2.80 (t, 4H,  $\text{NCH}_2$ ); 3.63 (s, 6H,  $\text{OCH}_3$ ); 9.11 (bs, 1H,  $\text{COOH}$ ).  $\delta_{\text{C}}$  31.5, 32.3, 48.3, 49.1, 51.2, 172.2, 175.6. IR 3410, 2955, 2844, 2622, 2490  $\text{cm}^{-1}$ .  $\lambda_{\text{max}}$  1735  $\text{cm}^{-1}$ . MS ( $\text{ES}^+$ )  $\text{MH}^+$  262.

### ***Specific Conditions for the Synthesis of AB<sub>2</sub> type Monomer 3.***

The ester-terminated intermediate 2 (53g, 0.203moles), was dissolved in 150ml anhydrous methanol and added dropwise, over a period of hour, to a stirred solution of ethylene diamine (81ml, 1.218moles) in methanol (200ml) at 0°C. After addition of the monomer was complete the reaction was stirred at room temperature under nitrogen for 7 days. Solvent and excess ethylene diamine was removed via rotary evaporation. Final traces of ethylene diamine were removed (as determined by GC and NMR) by placing the product under a high vacuum for 5 days (0.2mmHg). This gave the desired AB<sub>2</sub> type monomer as a thick orange oil, yield 98%. 250MHz NMR  $d_6$ -DMSO  $\delta_{\text{H}}$  2.08(bt, 2H,  $\text{CH}_2\text{COOH}$ ); 2.19 (bt, 4H,  $\text{CH}_2\text{CO}$ ); 2.50-2.70 (bm, 10H, residual  $\text{CH}_2$ 's); 3.10 (bq, 4H,  $\text{CH}_2\text{NH}$ ); 8.22 (bt, 2H,  $\text{NH}$ ).  $\delta_{\text{C}}$  34.4, 37.0, 40.7, 40.9, 50.8, 51.3, 173.5, 178.9. IR 3270, 3068, 2938, 2169, 1651  $\text{cm}^{-1}$ .  $\lambda_{\text{max}}$  1557  $\text{cm}^{-1}$ . MS (FAB)  $\text{MH}^+$  318.

### ***Specific Conditions for the Synthesis of Intermediate 4***

The AB<sub>2</sub> type monomer (12.158g,  $3.835 \times 10^{-2}$  moles in 50ml anhydrous methanol) was added dropwise to a stirred solution of methyl acrylate (21ml, 0.23moles) in methanol (50ml) over a period of 30 minutes at 0°C under a dry atmosphere. The reaction was then stirred for 2 days at room temperature. After the reaction was complete the excess methyl acrylate and solvent were removed under reduced pressure to give a thick orange oil, yield 98%. 250MHz NMR  $\text{CDCl}_3$   $\delta_{\text{H}}$  2.25-2.47 (m, 18H,  $\text{CH}_2\text{N}$ ); 2.55-2.85 (series of triplets, 14H,  $\text{CH}_2\text{CO}$ ); 3.15 (bq, 4H,  $\text{NHCH}_2$ ); 3.52 (s, 12H,  $\text{OCH}_3$ ); 7.02 (bt, 2H,  $\text{NH}$ ); 7.68 (bs, 1H,  $\text{COOH}$ ).  $\delta_{\text{C}}$  31.2, 32.1, 32.2, 32.4, 36.6, 48.7, 48.9, 51.4, 52.4, 61.9, 171.0, 172.7, 174.6. IR 3297, 2952, 2829, 2045  $\text{cm}^{-1}$ .  $\lambda_{\text{max}}$  1732  $\text{cm}^{-1}$ . MS (FAB)  $\text{MH}^+$  662.

### ***Specific Conditions for the Synthesis of AB<sub>x</sub> type Monomer 5***

The ester-terminated intermediate 4 (23.37g,  $3.536 \times 10^{-2}$  moles), was dissolved in 100ml anhydrous methanol and added dropwise over an hour to a stirred solution of ethylene diamine (190ml, 2.8moles) in methanol (100ml) at 0°C. After addition of the monomer was complete the reaction was stirred at room temperature for 9 days. Solvent and excess ethylene diamine was removed via rotary evaporation. Final traces of ethylene diamine were removed (as determined by GC and NMR) by placing the product under a high vacuum for 5 days (0.2mmHg). This gave the desired AB<sub>4</sub> monomer as thick orange oil in quantitative yield. 250MHz NMR d<sub>6</sub>-DMSO  $\delta_H$  2.10-2.30 (series of broad triplets, 14H, CH<sub>2</sub>CO); 2.40-2.75 (bm, 26H, residual CH<sub>2</sub>'s); 3.00-3.25 (bq, 12H, CH<sub>2</sub>NH); 8.06 (bt, 2H, NH); 8.36 (bt, 4H, NH).  $\delta_C$  34.6, 37.1, 38.0, 42.4, 43.3, 50.7, 51.1, 51.6, 52.2, 53.2, 172.9, 177.7. IR 3271, 3063, 2935, 2863, 2359, 2341 cm<sup>-1</sup>.  $\lambda_{max}$  1648 cm<sup>-1</sup>. MS (FAB) MH<sup>+</sup> 774.

***Specific Procedure for the Bulk Thermal Polymerisation of AB<sub>2</sub> and AB<sub>4</sub>-type Monomers***

The desired monomer was placed in a reaction tube and heated to 200°C, under high vacuum (standard laboratory pump, ~ 0.5mmHg), for 24 hours. The crude polymers were isolated as a glassy orange solids. Purification via membrane filtration (using a membrane bag with a 2.4nm cut-off ) provided the final polymer in 40-70% yield.

*Spectral data for AB<sub>2</sub>-type polymer:* 250MHz NMR d<sub>6</sub>-DMSO  $\delta_H$  1.00-4.50 (series of broad multiplets, NH) 1.0-2.8 (CH<sub>2</sub>N and CH<sub>2</sub>O H), 2.8-4.5 (CH<sub>2</sub>NH H); 7.70-8.80 (broad singlet, NH). 100MHz NMR d<sub>6</sub>-DMSO  $\delta_C$  29.3, 29.5, 31.5, 31.9, 32.6, 33.2, 33.4, 34.0, 36.5, 37.8, 38.5, 38.8, 39.5, 43.3, 43.7, 44.2, 45.7, 49.6, 49.8, 50.0, 50.3, 50.6, 51.0, 51.4, 51.8, 52.0, 52.2, 52.7, 53.0, 53.5, 54.1, 158.8, 168.2, 168.9, 171.3, 171.7, 172.5, 172.7, 173.0, 173.3, 173.4. GPC analysis (water, pH 4.5) M<sub>w</sub> 5828, PD 2.4, (M<sub>n</sub>+1 15707). TGA degradation onset 272°C, 10% wt. loss 331°C.

***Specific Procedure for Polycondensation of AB<sub>2</sub>-type Monomer using TPP/pyridine as Condensing Agent***

The AB<sub>2</sub>-type monomer (0.793g,  $2.5 \times 10^{-3}$  moles) was dissolved in NMP (2.5ml) with heating and then placed under a nitrogen atmosphere at 100°C. To the solution was added TPP (660μl,  $2.5 \times 10^{-3}$  moles) and pyridine (625μl,  $7.75 \times 10^{-3}$  moles) via syringe

and the reaction stirred under nitrogen at 100°C for 3½h. The final orange/red reaction mixture was then quenched with methanol (20ml) and precipitated into ethyl acetate (200ml). The polymer was isolated as a sticky yellow solid in 60% yield. 250MHz NMR  $d_6$ -DMSO  $\delta_H$  2.10-3.50 (series of broad multiplets, 58H relative to  $NH$ , all  $CH_2$  protons); 8.10-8.60 (broad singlet, 8H,  $NH$ ). 63MHz NMR  $d_6$ -DMSO  $\delta_C$  15.2, 21.9, 33.7, 34.3, 36.6, 37.1, 37.9, 38.7, 39.6, 39.8, 45.3, 50.3, 52.2, 60.9, 153.7, 153.8, GPC analysis (water, pH 4.5)  $M_w$  3409, PD 2.6,  $M_{z+1}$  12026. TGA degradation onset 153°C, 10% wt. loss 229°C.

#### *Alternative Procedures for Polycondensation of $AB_2$ -type and $AB_3$ -type Monomers using a Condensing Agent*

The  $AB_n$ -type monomer ( $1.0 \times 10^{-3}$  moles) in solvent (5ml) with warming in a 3-necked round bottomed flask. Nitrogen was bubbled through the monomer solution for 15 minutes then the condensing agent(s) ( $1.25 \times 10^{-3}$  moles) were added. The solution mixture was stirred until polymerisation was complete (as judged by GPC). The product was collected and purified via membrane filtration (using a membrane bag with a 2.4nm cut-off). Alternative condensing agents include triphenylphosphite/pyridine in N-methylpyrrolidinone (NMP) at various temperatures from 40-200°C or BOP (benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate) in NMP at temperatures from 20-100°C, DMT-MM (4-(4,6-dimethoxy-1,3,5-triazin-2yl)-4-methylmorpholinium chloride) in methanol or water at room temperature.

#### *Preliminary Transfection Results*

For all transfection experiments, 2µg of plasmid DNA (*lacZ*, 7.2kb) was mixed with 6µg of an  $AB_2$ -type hyperbranched polyamidoamine of the invention (A) and an  $AB_4$ -type hyperbranched polyamidoamine of the invention (B). These amounts resulted in complexes having a 1:3 ratio of DNA to hyperbranched polyamidoamine. The transfection efficiency against a variety of cell lines (including EAhy 926, HSVEC 1, HEK 293) was assessed using a standard  $\beta$ -galactosidase assay. The results for the hyperbranched polyamidoamines A and B for HEK 293 are shown in Figure 2 alongside the result for SUPERFECT<sup>R</sup> (C), a PAMAM dendrimer with 64 terminal groups (D) and a control (E).

FIGURE 1





FIGURE 2



THE PATENT OFFICE  
14 AUG 2003  
Received in Patents  
International Unit

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**